A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique

2K views

⸱

DOI:

10.3791/64671

⸱

September 23rd, 2022

 ,  ,  ,  ,  ,  ,  , 
1Beijing Key Laboratory of Pediatric Respiratory Infectious Diseases, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, Laboratory of Infection and Virology, Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, 2Research Unit of Critical Infection in Children, 2019RU016, Chinese Academy of Medical Sciences, 3Department of Pediatric Rehabilitation, Beijing Boai Hospital, School of Rehabilitation Medicine, Capital Medical University, China Rehabilitation Research Center, 4Center of Excellence (Beijing), Becton Dickinson Medical Devices (Shanghai) Co Ltd

* These authors contributed equally

In This Article

Summary

The present protocol combines ex vivo stimulation and flow cytometry to analyze polyfunctional T cell (TPF) profiles in peripheral blood mononuclear cells (PBMCs) within Japanese encephalitis virus (JEV)-vaccinated children. The detection method and flow cytometry color scheme of JEV-specific TPFs were tested to provide a reference for similar studies.

Abstract

T cell-mediated immunity plays an important role in controlling flavivirus infection, either after vaccination or after natural infection. The "quality" of a T cell needs to be assessed by function, and higher function is associated with more powerful immune protection. T cells that can simultaneously produce two or more cytokines or chemokines at the single-cell level are called polyfunctional T cells (TPFs), which mediate immune responses through a variety of molecular mechanisms to express degranulation markers (CD107a) and secrete interferon (IFN)-γ, tumor necrosis factor (TNF)-α, interleukin (IL)-2, or macrophage inflammatory protein (MIP)-1α. There is increasing evidence that TPFs are closely related to the maintenance of long-term immune memory and protection and that their increased proportion is an important marker of protective immunity and is important in the effective control of viral infection and reactivation. This evaluation applies not only to specific immune responses but also to the assessment of cross-reactive immune responses. Here, taking the Japanese encephalitis virus (JEV) as an example, the detection method and flow cytometry color scheme of JEV-specific TPFs produced by peripheral blood mononuclear cells of children vaccinated against Japanese encephalitis were tested to provide a reference for similar studies.

Introduction

Japanese encephalitis virus (JEV) is an important mosquito-borne virus belonging to the genus Flavivirus within the Flaviviridae family1. Many Asia-Pacific countries have long faced enormous public health challenges due to the huge disease burden caused by Japanese encephalitis (JE), but this has improved dramatically with the increasing availability of various types of vaccinations2. Adaptive protective immune responses evoked by natural infection or vaccination contribute to the prevention and antiviral regulation. Humoral immunity and cell-mediated immunity are classified as adaptive immunity, and the induction of the former has always been regarded as a key strategy in vaccine design, albeit with relatively limited understanding in the past3. However, the role of T cell-mediated immunity in limiting flavivirus dissemination and virus clearance has been increasingly focused on and extensively studied4. Furthermore, T cell immunity is not only indispensable in JEV-specific antiviral responses but also plays a prominent role in cross-protection from secondary infection with heterologous flaviviruses, which has been demonstrated in previous studies5. It is speculated that this effect may bypass potential antibody-mediated enhancement effects in infection5. Of note, such cross-reactive T cell immunity is important, especially in the absence of vaccines and antiviral drugs against flaviviruses. Although many studies have been performed to determine the contribution of T cells in JEV infection with respect to CD4+ and CD8+ T cells6,7, the respective lineages secreting cytokines and their functional diversification remain undetermined, which means the elucidation of the exact functions of helper and killer T cells is hindered.

The scale of their antiviral defenses determines the quality of T cell responses. CD4+ or CD8+ T cells that can compatibly confer two or more functions, including cytokine secretion and degranulation, are characterized as polyfunctional T cells (TPFs) upon specific stimulation at the single-cell level8. CD4+ T cells that produce single or multiple cytokines may have various effects and immune memories. For example, IL-2+ IFN-γ+ CD4+ T cells are more likely to form a long-term effective protective response than IL-2+ CD4+ T cells9, which can be used as an important parameter in evaluating the vaccination effect. The frequency of IL-2+ IFN-γ+ CD4+ T cells is increased in patients with long-term non-progression of acquired immune deficiency syndrome (AIDS), while CD4+ T cells in patients with AIDS progression are more inclined to produce IFN-γ alone due to the promoting effect of IL-2 on T cell proliferation10. Furthermore, a subset of IL-2+ IFN-γ+ TNF-α+ was shown to survive long-term in vivo and synergistically promote the killing function11. Although CD8+ T cells are more likely to exhibit cytotoxic activity, some CD4+ T cells are also equipped with cytotoxic activity as an indirectly detected expression of surface CD107a molecules12. In addition, certain T cell subsets express the chemokine MIP-1α, which is often secreted by monocytes to participate in T cell-mediated neutrophil recruitment13. Similarly, CD8+ TPFs can also be used to characterize the versatility of the above markers. Studies have shown that the prime-boost strategy can effectively induce a prolonged period of TPF protective effects13, which can enhance the protection elicited by vaccination. A central feature in examining the immune system is the ability of memory T cells to facilitate stronger, faster, and more effective responses to secondary viral challenges than naïve T cells. Effector memory T cells (TEM) and central memory T cells (TCM) are important T cell subsets that are often differentiated by the composite expression of CD27/CD45RO or CCR7/CD45RA14. TCM (CD27+ CD45RO+ or CCR7+ CD45RA-) tends to localize in secondary lymphoid tissues, while TEM (CD27- CD45RO+ or CCR7- CD45RA-) localizes in lymphoid and peripheral tissues15,16. TEM provides immediate but not sustained defense, whereas TCM sustains the response by proliferating in the secondary lymphoid organs and generating new effectors17. Thus, given that memory cells can mediate specific and efficient recall responses to viruses, questions arise about the contribution of this subset of polyfunctions.

With the development of flow cytometry technology, it has become common to simultaneously detect markers of more than 10 clusters, phenotypes, and differentiation antigens, which is beneficial to more abundantly annotate the functional immunological features on individual T cells to reduce misinterpretation and difficulties in understanding of T cell phenotypes. This study used ex vivo stimulation and flow cytometry to analyze TPF profiles in peripheral blood mononuclear cells (PBMCs) within JEV-vaccinated children. Applying this approach, the understanding of short- and long-term JEV-specific and even cross-reactive T cell immunity induced by vaccination will be expanded.

Access restricted. Please log in or start a trial to view this content.

Protocol

Ethical approval for the present study was obtained by the Ethics Committee of Beijing Children's Hospital, Capital Medical University (Approval Number: 2020-k-85). Volunteers were recruited from Beijing Children's Hospital, Capital Medical University. Peripheral venous blood samples were obtained from apparently healthy children (2 years old) who had previously received a prime and boosted vaccination with live-attenuated JE SA14-14-2 vaccine for less than half a year (JE-vaccinated children, n = 5) and unvaccinated children (6 months old, n = 5). Informed consent of human subjects was waived as only the residual samples, after being clinically tested, were used in this study. To protect the privacy of the volunteers, all data were fully anonymized and de-identified.

1. Isolation of PBMCs from peripheral venous blood

  1. Collect peripheral venous blood samples (2 mL) from JE-vaccinated and unvaccinated children in EDTA-K2-anticoagulated tubes (see Table of Materials) by the standard venipuncture technique18.
  2. Add 2 mL of phosphate-buffered saline (1x PBS) to dilute the peripheral blood.
    NOTE: The process is handled as soon as possible to maintain maximum survivability.
  3. Add 4 mL of the density gradient medium (see Table of Materials) to a 15 mL centrifuge tube, and slowly transfer the diluted blood to the upper layer of the separation medium.
    NOTE: Do not mix the blood with the separation medium or destroy the contact surface formed by the two liquids; otherwise, the separation effect will not be achieved.
  4. Centrifuge at 800 × g for 20 min at room temperature. Observe the significant layers after centrifugation.
  5. Transfer the PBMCs (the middle layer) to another 15 mL centrifuge tube, and wash the PBMCs with 10 mL of RPMI-1640 medium containing 10% fetal bovine serum (FBS, see Table of Materials).
  6. Centrifuge at 800 × g for 10 min at room temperature and discard the supernatant with a pipette carefully.
  7. Resuspend the PBMCs with 1 mL of RPMI-1640 medium containing 10% FBS and count the cells with a trypan blue-based automated counter (see Table of Materials).

2. Stimulation of PBMCs by inactivated JEV particles to induce cytokine expression

  1. Set two subgroups of the JEV stimulation and control groups in the JE-vaccinated and unvaccinated samples, respectively.
  2. Adjust the number of PBMCs to 2 × 106 cells/mL with RPMI-1640 medium containing 10% FBS, and seed the PBMCs in 24-well plates (2 × 106 cells/1 mL medium per well); inoculate three wells for each group.
  3. Stimulate the PBMCs of the JEV stimulation group with concentrated inactivated JEV particles5 (2 × 105 PFU) for 16 h at 37 °C in the presence of monoclonal antibodies CD28 (1 µg/mL, 1:1,000) and CD49d (1 µg/mL), GolgiPlug (1 µg/mL, 1:1,000), and monensin (1 µg/mL, 1:1,000). For surface staining, use BV605-anti-CD107a (1 µg/mL, 1:1,000) (see Table of Materials).
    NOTE: The JEV was inactivated by UV irradiation as described previously19.
  4. Stimulate the PBMCs of the control group without concentrated virus particles for 16 h at 37 °C in the presence of monoclonal antibodies CD28 (1 µg/mL, 1:1,000) and CD49d (1 µg/mL, 1:1,000), GolgiPlug (1 µg/mL, 1:1,000), and monensin (1 µg/mL, 1:1,000). Stain the surface with BV605-anti-CD107a (1 µg/mL, 1:1,000).

3. Ex vivo intracellular staining

  1. Collect the cell suspension from each group in a 1.5 mL microcentrifuge tube, centrifuge at 500 × g for 5 min at room temperature, and remove the supernatant with a pipette.
  2. Resuspend the cells in 1 mL of 1x PBS, add fixable viability dye (1 µL/mL, 1:1,000, see Table of Materials) to the cell suspension, and incubate for 10 min at room temperature in the dark. Centrifuge at 500 × g (at room temperature) for 5 min and remove the supernatant.
  3. Resuspend the cells in 1 mL of 1x PBS. Centrifuge at 500 × g (at room temperature) for 5 min. Discard the supernatant carefully.
  4. Perform cell surface marker staining.
    1. Resuspend the cells in 100 µL of 1x PBS, and add 2 µL of each surface markers antibody (BV650-anti-CD3, BUV395-anti-CD4, BV421-anti-CD8, BUV737-anti-CD27, and BV480-anti-CD45RO, dilution factor: 1:50, see Table of Materials) to the cell suspension in each tube.
      NOTE: The color fluorescent antibody staining protocol is shown in Table 1.
    2. Incubate the tubes (step 3.4.1) for 30 min at room temperature, and protect them from light. Centrifuge at 500 × g for 5 min and remove the supernatant.
      NOTE: The antibody of BUV737-anti-CD27 and BV480-anti-CD45RO can be replaced with BUV737-anti-CCR7 and BV480-anti-CD45RA as the annotation of the memory T cells.
  5. Resuspend the cells in 1 mL of 1x PBS. Centrifuge at 500 × g for 5 min at room temperature. Discard the supernatant carefully.
  6. Perform fixation and membrane breaking.
    1. Resuspend the cells with 500 µL of membrane-breaking fixative solution (see Table of Materials) and fix the cells for 20 min in the dark at room temperature. Centrifuge at 500 × g for 5 min and remove the supernatant.
  7. Resuspend the cells in 1 mL of 1x PBS. Centrifuge for 5 min at 500 × g at room temperature and remove the supernatant carefully.
  8. Perform intracellular cytokine staining.
    1. Resuspend the cells in 100 µL of 1x PBS, and add 2 µL of each cytokine antibody (FITC-anti-IFN-γ, PE-anti-TNF-α, BV785-anti-IL-2, and APC-anti-MIP-1α, dilution factor: 1:50, see Table of Materials) to the cell suspension in each tube.
      NOTE: The volumes and information on fluorophore conjugated antibodies are shown in Table 1.
    2. Incubate the tubes (step 3.8.1) for 30 min at room temperature in the dark. Centrifuge at 500 × g for 5 min and remove the supernatant.
  9. Resuspend the cells in 1 mL of 1x PBS. Centrifuge at 500 × g for 5 min at room temperature, and remove the supernatant carefully. Add 500 µL of 1x PBS to resuspend the cells.

4. Flow cytometry set-up

  1. Isolate the PBMC sample alone following the procedures described in step 1 as the control sample. Divide the cell suspension into 12 equal parts in 1.5 mL microcentrifuge tubes (100 µL/tube) as mentioned below.
    1. Set up unstained, APC-Cy7-live/dead fixable stained, BV650-anti-CD3 single-stained, BUV395-anti-CD4 single-stained, BV421-anti-CD8 single-stained, BUV737-anti-CD27 single-stained, BV480-anti-CD45RO stained, BV605-anti-CD107a, FITC-anti-IFN-γ stained, PE-anti-TNF-α single-stained, BV785-anti-IL-2 single-stained, and APC-anti-MIP-1α single-stained samples.
  2. Add the cell surface markers and intracellular cytokine staining as described in step 3. For each single-staining sample, only add one of the fluorophores from the staining step. Add 500 µL of 1x PBS to resuspend the cells and vortex with low velocity.
  3. Using an unstained sample, adjust the forward scatter (FSC), side scatter (SSC), and different fluorescent dye voltages.
    NOTE: For the present study, the following voltages were set. FSC: 440 V, SSC: 233 V, BV650: 575 V, APC-Cy7: 449 V, BUV395: 500 V, BV421: 402 V, BUV737: 585 V, BV480: 444 V, BV605: 457 V, FITC: 475 V, PE: 469 V, APC: 623 V, and BV785: 725 V.
  4. Using the single-staining samples, adjust the flow cytometry compensation to eliminate the contamination signals between the different fluorophores.
    ​NOTE: The compensation parameters are shown in Table 2.

5. Gating strategy and data analysis

NOTE: In the present study, for this analysis, the central memory T cells (TCM of CD8+ or CD4+ T cells as CD27+ CD45RO+ or CCR7+ CD45RA- and the effector memory T cells (TEM) of CD8+ or CD4+ T cells as CD27- CD45RO+ or CCR7- CD45RA- were defined respectively16.

  1. Draw a polygon gate through the FSC-area (FSC-A)/SSC-area (SSC-A) dot plot to select the intact lymphocyte population while excluding the debris (Figure 1A).
  2. Draw a rectangular gate through the FSC-A/FSC-width (FSC-W) dot plot to select the single cells (Figure 1B).
  3. Draw a rectangular gate through the live/dead/SSC-A dot plot to select the live cells (Figure 1C).
  4. Draw a rectangular gate through the CD3/SSC-A dot plot to identify the CD3+ T cells (Figure 1D).
  5. Draw a quad gate through the CD4/CD8 dot plot to identify the CD4+ or CD8+ T cells (Figure 1E).
  6. Draw a quad gate through the CD45RO/CD27 dot plot to subdivide the CD4+ or CD8+ T cells into TCM (CD27+ CD45RO+) and TEM (CD27- CD45RO+) (Figure 1F-I).
  7. Draw the gates of CD107a, IFN-γ, TNF-α, IL-2, and MIP-1α from the TCM or TEM of the CD8+ or CD4+ T cells to determine the frequency of different response patterns, respectively.
  8. Load the samples onto the cytometry sequentially. Use a stopping gate20 to acquire 1 × 106 lymphocytes.
    NOTE: The individual user can collect more than 1 × 106 cells. This number was a compromise between the time taken and the collection of enough cells to provide meaningful results.

Access restricted. Please log in or start a trial to view this content.

Results

Figure 1 shows the gating strategy used to divide the TCM or TEM of CD8+ or CD4+ T cells from a representative JEV stimulation group of JE-vaccinated children. The FSC-A/SSC-A dot plot is used to identify lymphocytes, and the FSC-A/FSC-W dot plot is used to identify single cells. Viable cells are selected on the live/dead/SSC-A dot plot. The CD3/SSC-A dot plot is used to identify the CD3+ T cells. The CD4/CD8 dot plot is used to identify...

Access restricted. Please log in or start a trial to view this content.

Discussion

This protocol represents a feasible flow cytometry-based detection method for TPF profiles in the PBMCs of children vaccinated with the JEV vaccine SA14-14-2. This study used the venous blood PBMCs of both vaccinated and unvaccinated children as research materials. With the stimulation of PBMCs with the JEV antigen, those amplified antigen-specific TPFs can be characterized by multicolor flow cytometry antibody staining. Compared with the conventional enzyme-linked immunospot assay method, flow cyto...

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have nothing to disclose.

Acknowledgements

R.W. was supported by National Natural Science Foundation of China (82002130), Beijing Natural Science Foundation of China (7222059). ZD.X. was supported by the CAMS Innovation Fund for Medical Sciences (2019-I2M-5-026).

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
anti-human CD28Biolegend302934Antibody
anti-human CD49dBiolegend304339Antibody
APC anti-human MIP-1αBD551533Fluorescent antibody 
Automated cell counterBIO RADTC20Cell count
BD FACSymphony A5BDA5flow Cytometry
BUV395 anti-human CD4BD563550Fluorescent antibody 
BUV737 anti-human CCR7BD741786Fluorescent antibody 
BUV737 anti-human CD27BD612829Fluorescent antibody 
BV421 anti-human CD8Biolegend344748Fluorescent antibody 
BV480 anti-human CD45RABD566114Fluorescent antibody 
BV480 anti-human CD45ROBD566143Fluorescent antibody 
BV605 anti-human CD107aBiolegend328634Fluorescent antibody 
BV650 anti-human CD3BD563999Fluorescent antibody 
BV785 anti-human IL-2Biolegend500348Fluorescent antibody 
Centrifuge TubeBD FalconBD-3520971515 mL centrifuge tube
Cytofix/Cytoperm Fixation/Permeabilization Solution KitBD554714Cell fixation and permeabilization
Density gradient mediumDakeweDKW-KLSH-0100Ficoll-Paque, human lymphocyte separation medium
FITC anti-human IFN-γBiolegend502506Fluorescent antibody 
Gibco Fetal Bovine SerumThermo Fisher Scientific16000-044Fetal Bovine Serum
Gibco RPMI-1640 mediumThermo Fisher Scientific22400089cell culture medium
High-speed centrifugeSigma 3K15Cell centrifugation for 15 mL centrifuge tube
High-speed centrifugeEppendorf5424RCell centrifugation for 1.5 mL Eppendorf (EP) tube
Microcentrifuge tubesAxygenMCT-150-C1.5 mL microcentrifuge tube
PE anti-human TNF-αBiolegend502909Fluorescent antibody 
Phosphate Buffered Saline (PBS)BI02-024-1ACSPBS
Protein Transport Inhibitor (Containing Brefeldin A, GolgiPlug)BD555029blocks intracellular protein transport processes
Protein Transport Inhibitor (Containing Monensin)BD554724blocks intracellular protein transport processes
Round-bottom test tubeBD Falcon3522355 mL test tube
Trypan Blue Staining Cell Viability Assay KitBeyotimeC0011Trypan Blue Staining
Zombie NIR Fixable Viability DyeBiolegend423106Dead cell stain

References

  1. Vanden Eynde, C., Sohier, C., Matthijs, S., De Regge, N. Japanese encephalitis virus interaction with mosquitoes: A review of vector competence, vector capacity and mosquito immunity. Pathogens. 11 (3), 317(2022).
  2. Wang, R., et al. The epidemiology and disease burden of children hospitalized for viral infections within the family Flaviviridae in China: A national cross-sectional study. PLoS Neglected Tropical Diseases. 16 (7), 0010562(2022).
  3. Wang, R., et al. Decreases in both the seroprevalence of serum antibodies and seroprotection against Japanese encephalitis virus among vaccinated children. Virologica Sinica. 34 (3), 243-252 (2019).
  4. Wang, R., et al. Neutralizing antibody rather than cellular immune response is maintained for nearly 20 years among Japanese encephalitis SA14-14-2 vaccinees in an endemic setting. Infection, Genetics and Evolution. 85, 104476(2020).
  5. Wang, R., et al. T cell immunity rather than antibody mediates cross-protection against Zika virus infection conferred by a live attenuated Japanese encephalitis SA14-14-2 vaccine. Applied Microbiology and Biotechnology. 104 (15), 6779-6789 (2020).
  6. Redant, V., Favoreel, H. W., Dallmeier, K., Van Campe, W., De Regge, N. Japanese encephalitis virus persistence in porcine tonsils is associated with a weak induction of the innate immune response, an absence of IFNgamma mRNA expression, and a decreased frequency of CD4(+)CD8(+) double-positive T cells. Frontiers in Cellular and Infection Microbiology. 12, 834888(2022).
  7. Jain, N., et al. CD8 T cells protect adult naive mice from JEV-induced morbidity via lytic function. PLoS Neglected Tropical Diseases. 11 (2), 0005329(2017).
  8. Khakhum, N., Bharaj, P., Walker, D. H., Torres, A. G., Endsley, J. J. Antigen-specific antibody and polyfunctional T cells generated by respiratory immunization with protective Burkholderia DeltatonB Deltahcp1 live attenuated vaccines. NPJ Vaccines. 6 (1), 72(2021).
  9. Weaver, J. M., et al. Increase in IFNgamma(-)IL-2(+) cells in recent human CD4 T cell responses to 2009 pandemic H1N1 influenza. PloS One. 8 (-), 57275(2013).
  10. Boaz, M. J., Waters, A., Murad, S., Easterbrook, P. J., Vyakarnam, A. Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection. Journal of Immunology. 169 (11), 6376-6385 (2002).
  11. Gui, L., et al. IL-2, IL-4, IFN-gamma or TNF-alpha enhances BAFF-stimulated cell viability and survival by activating Erk1/2 and S6K1 pathways in neoplastic B-lymphoid cells. Cytokine. 84, 37-46 (2016).
  12. Terahara, K., et al. Vaccine-induced CD107a+ CD4+ T cells are resistant to depletion following AIDS virus infection. Journal of Virology. 88 (24), 14232-14240 (2014).
  13. Tanyi, J. L., et al. Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer. NPJ Vaccines. 6 (1), 36(2021).
  14. Ammirati, E., et al. Effector memory T cells are associated with atherosclerosis in humans and animal models. Journal of the American Heart Association. 1 (1), 27-41 (2012).
  15. Rizk, N. M., Fadel, A., AlShammari, W., Younes, N., Bashah, M. The immunophenotyping changes of peripheral CD4+ T lymphocytes and inflammatory markers of class III obesity subjects after laparoscopic gastric sleeve surgery - A follow-up study. Journal of Inflammation Research. 14, 1743-1757 (2021).
  16. Zhang, Y., et al. Phenotypic and functional characterizations of CD8(+) T cell populations in malignant pleural effusion. Experimental Cell Research. 417 (1), 113212(2022).
  17. Shin, H., Iwasaki, A. Tissue-resident memory T cells. Immunological Reviews. 255 (1), 165-181 (2013).
  18. Birnie, K. A., Noel, M., Chambers, C. T., Uman, L. S., Parker, J. A. Psychological interventions for needle-related procedural pain and distress in children and adolescents. Cochrane Database of Systematic Reviews. 10 (10), (2018).
  19. Lin, R. J., Liao, C. L., Lin, Y. L. Replication-incompetent virions of Japanese encephalitis virus trigger neuronal cell death by oxidative stress in a culture system. Journal of General Virology. 85, 521-533 (2004).
  20. Byford, E., Carr, M., Pinon, L., Ahearne, M. J., Wagner, S. D. Isolation of CD4+ T-cells and analysis of circulating T-follicular helper (cTfh) cell subsets from peripheral blood using 6-color flow cytometry. Journal of Visualized Experiments. (143), e58431(2019).
  21. Zheng, X., et al. Immune responses and protective effects against Japanese encephalitis induced by a DNA vaccine encoding the prM/E proteins of the attenuated SA14-14-2 strain. Infection, Genetics and Evolution. 85, 104443(2020).
  22. Zheng, X., et al. Complete protection for mice conferred by a DNA vaccine based on the Japanese encephalitis virus P3 strain used to prepare the inactivated vaccine in China. Virology Journal. 17 (1), 126(2020).
  23. Lam, J. K. P., et al. Emergence of CD4+ and CD8+ polyfunctional T cell responses against immunodominant lytic and latent EBV antigens in children with primary EBV infection. Frontiers in Microbiology. 9, 416(2018).
  24. Meckiff, B. J., et al. Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4(+) T cells in COVID-19. Cell. 183 (5), 1340-1353 (2020).
  25. Ning, R. J., Xu, X. Q., Chan, K. H., Chiang, A. K. Long-term carriers generate Epstein-Barr virus (EBV)-specific CD4(+) and CD8(+) polyfunctional T-cell responses which show immunodominance hierarchies of EBV proteins. Immunology. 134 (2), 161-171 (2011).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Tags

T Cell ImmunityIntracellular Cytokine StainingPeripheral Blood Mononuclear CellsCD4 Positive T CellsCD8 Positive T CellsDegranulation MarkersImmune Memory
Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique
Contact Us
Recommend to Library

Privacy

Terms of Use

Policies

Copyright © 2026 MyJoVE Corporation. All rights reserved.